

**REFMAL 314 DDU - REFMAL 314**

A PHASE IB DOSE-ESCALATION STUDY OF LCL161 IN COMBINATION WITH ORAL TOPOTECAN FOR PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG (SCLC) AND SELECT GYNECOLOGIC MALIGNANCIES

**Cancer types:** GYN, ovarian

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 384 DDU - D6010C00005**

A PHASE IB STUDY OF AZD1775 AND OLAPARIB IN PATIENTS WITH REFRACTORY SOLID TUMOURS

**Cancer types:** Lung Small Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 449 DDU - CK-101-101**

A PHASE 1/2 OPEN-LABEL SAFETY PHARMACOKINETIC AND EFFICACY STUDY OF ASCENDING DOSES OF ORAL CK-101 IN PATIENTS WITH ADVANCED SOLID TUMORS

**Cancer types:** Lung NCSLC Non-Squamous, T790 EGFR mutated

**Lines of therapy:** 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

**REFMAL 452 DDU - 4020-01-001**

A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022 AN ANTI-TIM-3 MONOCLONAL ANTIBODY IN PATIENTS WITH ADVANCED SOLID TUMORS

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Melanoma

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 460 DDU - CA-170-101**

A PHASE 1 OPEN-LABEL DOSE ESCALATION AND DOSE EXPANSION TRIAL EVALUATING THE SAFETY PHARMACOKINETICS PHARMACODYNAMICS AND CLINICAL EFFECTS OF ORALLY ADMINISTERED CA-170 IN PATIENTS WITH ADVANCED TUMORS AND LYMPHOMAS

**Cancer types:** Bladder, Breast Triple Negative, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 463 DDU - I8S-MC-JUAB**

A PHASE 1 STUDY OF A ERK1/2 INHIBITOR (LY3214996) ADMINISTERED ALONE OR IN COMBINATION WITH OTHER AGENTS IN ADVANCED CANCER

**Cancer types:** Bladder, Colorectal, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Melanoma, Pancreas/Biliary, RAS mutation, braf

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 470 DDU - BTP-114-001**

A PHASE 1 OPEN-LABEL DOSE ESCALATION STUDY OF INTRAVENOUS ADMINISTRATION OF SINGLE AGENT BTP-114 IN PATIENTS WITH ADVANCED SOLID TUMORS AND A KNOWN DELETERIOUS BRCA OR DNA REPAIR MUTATION

**Cancer types:** Bladder, Breast Triple Negative, GYN, BRCA mutated

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 476 DDU - LYC-55716-1001**

A PHASE 1/2A MULTICENTER OPEN-LABEL STUDY OF LYC-55716 IN ADULT SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC CANCER

**Cancer types:** Head & Neck, Renal Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**BRE 260 - CP-MGAH22-04**

A PHASE 3 RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS. TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT

**Cancer types:** Breast ER+, Breast HER2+

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**BRE 271 - ONT-380-206**

PHASE 2 RANDOMIZED DOUBLE-BLINDED CONTROLLED STUDY OF ONT-380 VS. PLACEBO IN COMBINATION WITH CAPECITABINE AND TRASTUZUMAB IN PATIENTS WITH PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2+ BREAST CARCINOMA

**Cancer types:** Breast HER2+

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**BRE 274 - INO-VT-464-CL-006**

A PHASE 1/2 OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF SEVITERONEL IN SUBJECTS WITH ADVANCED BREAST CANCER

**Cancer types:** Breast ER+, Breast Triple Negative

**Lines of therapy:** 2nd Line Metastatic

**CLL 31 - IPI-145-12**

A STUDY OF IPI-145 AND OFATUMUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA PREVIOUSLY ENROLLED IN STUDY IPI-145-07 (CLL 30 ROLLOVER STUDY)

**Cancer types:** Lymphoma/Leukemia

**Lines of therapy:** Other

**CLL 39 - UTX-TGR-204**

A MULTI-CENTER OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF UBLITUXIMAB (TG-1101) IN COMBINATION WITH TGR-1202 FOR PATIENTS PREVIOUSLY ENROLLED IN PROTOCOL UTX-TGR-304

**Cancer types:** Lymphoma/Leukemia

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**GI 201 - GI 201**

A PHASE II STUDY OF NAB-PACLITAXEL PLUS RAMUCIRUMAB FOR THE SECOND-LINE TREATMENT OF PATIENTS WITH METASTATIC GASTROESOPHAGEAL CANCER

**Cancer types:** Esophageal, Gastric

**Lines of therapy:** 2nd Line Metastatic

**GI 238 - CA209577**

A RANDOMIZED MULTICENTER DOUBLE BLIND PHASE III STUDY OF ADJUVANT NIVOLUMAB OR PLACEBO IN SUBJECTS WITH RESECTED ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER

**Cancer types:** Esophageal

**Lines of therapy:** Adjuvant

**GI 241 - CA209649**

A RANDOMIZED MULTICENTER OPEN-LABEL PHASE 3 STUDY OF NIVOLUMAB PLUS IPILIMUMAB OR NIVOLUMAB IN COMBINATION WITH OXALIPLATIN PLUS FLUOROPYRIMIDINE VERSUS OXALIPLATIN PLUS FLUOROPYRIMIDINE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER

**Cancer types:** Esophageal, Gastric

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GI 245 - ISB-MC-JGDP**

A PHASE 2 (RANDOMIZED DOUBLE-BLINDED) STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF FIRST-LINE METASTATIC PANCREATIC CANCER

**Cancer types:** Pancreas/Biliary

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GI 247 - CanStem303C**

A PHASE III STUDY OF BBI-608 IN COMBINATION WITH 5-FLUOROURACIL LEUCOVORIN IRINOTECAN (FOLFIRI) IN ADULT PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (CRC)

**Cancer types:** Colorectal

**Lines of therapy:** 2nd Line Metastatic

**GU 134 - WO30070**

A PHASE III MULTICENTER RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY

**Cancer types:** Bladder

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GU 135 - MK-3475-361-00**

A PHASE III RANDOMIZED CONTROLLED CLINICAL TRIAL OF PEMBROLIZUMAB WITH OR WITHOUT PLATINUM-BASED COMBINATION CHEMOTHERAPY VERSUS CHEMOTHERAPY IN SUBJECTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

**Cancer types:** Bladder

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GU 144 - D5082c00003**

A PHASE III OPEN LABEL RANDOMISED CONTROLLED MULTI-CENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF SAVOLITINIB VERSUS SUNITINIB IN PATIENTS WITH MET-DRIVEN UNRESECTABLE/LOCALLY ADVANCED OR METASTATIC PAPILLARY RENAL CELL CARCINOMA (PRCC)

**Cancer types:**

**Lines of therapy:**

**GYN 72 - FRV-004**

A RANDOMIZED MULTICENTER PHASE II TRIAL TO EVALUATE THE SAFETY EFFICACY AND IMMUNOGENICITY OF VACCINATION WITH FOLATE RECEPTOR ALPHA PEPTIDES ADMIXED WITH GM-CSF AS A VACCINE ADJUVANT VERSUS GM-CSF ALONE IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER

**Cancer types:** GYN

**Lines of therapy:** Adjuvant

**HEMREF 35 DDU - 13-601**

A PHASE I OPEN-LABEL MULTI-DOSE DOSE ESCALATION STUDY OF PRT062070 IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) OR B-CELL NON HODGKIN LYMPHOMA (NHL)

**Cancer types:** Lymphoma/Leukemia, PTCL, CTCL

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**MULTI 05 DDU - RXDX-101-02**

AN OPEN-LABEL MULTICENTER GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3 ROS1 OR ALK GENE REARRANGEMENTS

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor, NTRK or ROS mutations

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 351 DDU - I4D-MC-JTJF**

A PHASE 1B TRIAL OF LY2606368 IN COMBINATION WITH EITHER CISPLATIN OR CETUXIMAB IN ADVANCED OR METASTATIC TUMORS

**Cancer types:** Breast Triple Negative

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 360 DDU - MGCD516-001**

A PHASE 1/1B STUDY OF MGCD516 IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor, KIT,FLT3,RET,PDGFR,TRK,CBL,DDR2,KDR mutations

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 367 DDU - ALRN-6924-1-01**

A PHASE I/II OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF ALRN-6924 IN PATIENTS WITH ADVANCED SOLID TUMORS EXPRESSING WILD-TYPE P53 PROTEIN

**Cancer types:** PTCL

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 390 DDU - D6130C00001**

A PHASE I OPEN-LABEL MULTICENTRE DOSE ESCALATION STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF AZD2811 IN PATIENTS WITH ADVANCED SOLID TUMOURS

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 407 DDU - 2015-012-00US1**

A MULTI-CENTER OPEN-LABEL CLINICAL TRIAL TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS OF SULFATINIB IN ADVANCED SOLID TUMORS

**Cancer types:** Biliary, PNET

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 412 DDU - D6015C00002**

A PHASE I STUDY ASSESSING THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF AZD1775 IN COMBINATION WITH MEDI4736 IN PATIENTS WITH ADVANCED SOLID TUMOURS

**Cancer types:** Bladder, Breast Triple Negative, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 430 DDU - STML-801-0115**

A PHASE 1 STUDY OF SL-801 A REVERSIBLE INHIBITOR OF NUCLEAR EXPORT IN PATIENTS WITH ADVANCED SOLID TUMORS

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 434 DDU - B9991004**

A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB\* (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES

**Cancer types:** Head & Neck

**Lines of therapy:** 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 435 - D8730C00001**

A PHASE I, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF ASCENDING DOSES OF AZD4635 BOTH AS MONOTHERAPY AND IN COMBINATION WITH DURVALUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Prostate, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**LUN 326 - CA209-384**

A DOSE FREQUENCY OPTIMIZATION TRIAL OF NIVOLUMAB 240 MG EVERY 2 WEEKS VS 480 MG EVERY 4 WEEKS IN ADVANCED OR METASTATIC NSCLC PATIENTS WHO RECEIVED 12 MONTHS OF NIVOLUMAB AT 3 MG/KG OR 240 MG EVERY 2 WEEKS

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous

**Lines of therapy:** 1st Line Metastatic - Locally Advanced, Other

**LYM 115 - BGB-3111-GA-101**

PHASE 1B STUDY TO ASSESS SAFETY, TOLERABILITY AND ANTITUMOR ACTIVITY OF THE COMBINATION OF BGB-3111 WITH OBINUTUZUMAB IN SUBJECTS WITH B-CELL LYMPHOID MALIGNANCIES

**Cancer types:** Lymphoma/Leukemia

**Lines of therapy:** 2nd Line Metastatic

**LYM 120 - UTX-TGR-205**

A PHASE 2B RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF THE COMBINATION OF UBLITUXIMAB + TGR-1202 WITH OR WITHOUT BENDAMUSTINE AND TGR-1202 ALONE IN PATIENTS WITH PREVIOUSLY TREATED NON-HODGKIN'S LYMPHOMA.

**Cancer types:** Lymphoma/Leukemia

**Lines of therapy:** 2nd Line Metastatic

**LYM 126 - PCYC-1141-CA**

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB, IN COMBINATION WITH RITUXIMAB VERSUS PLACEBO IN COMBINATION WITH RITUXIMAB IN TREATMENT NAIVE SUBJECTS WITH FOLLICULAR LYMPHOMA

**Cancer types:** Lymphoma/Leukemia

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**LUN 305 - D5164C00001**

PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF AZD9291/PLACEBO IN PATIENTS WITH EGFR MUTATION POSITIVE STAGE IB-IIIa NSCLC FOLLOWING COMPLETE TUMOR RESECTION WITH OR WITHOUT ADJUVANT CHEMOTHERAPY

**Cancer types:** Lung NCSLC Non-Squamous

**Lines of therapy:** Adjuvant

**MM 74 - NSMM-5001**

AN OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PARTICIPANTS

**Cancer types:** Myeloma

**Lines of therapy:** 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

**MULTI 12 - CA209-627**

AN OPEN-LABEL PHASE 2 MULTI-COHORT TRIAL OF NIVOLUMAB IN ADVANCED OR METASTATIC MALIGNANCIES

**Cancer types:** GYN, Solid Tumor

**Lines of therapy:** 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

**PRO 02 - ML28897**

PHASE 2A STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB, AND VISMODEGIB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**PRO 10 - PRO 10**

STUDY TO ASSESS THE ACTIVITY OF MOLECULARLY MATCHED TARGETED THERAPIES (REGORAFENIB OR AFATINIB) IN SELECT TUMOR TYPES BASED ON GENOMIC ALTERATIONS

**Cancer types:** Bladder, Esophageal, Gastric, Head & Neck, Hepatocellular, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Pancreas/Biliary, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic

**REFMAL 383 - D6015C00001**

A PHASE IB, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOUR ACTIVITY OF AZD1775 MONOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMOURS

**Cancer types:** Breast Triple Negative, GYN, Lung Small Cell, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**GU 140 DDU - D9320C00001**

A PHASE 1/1B MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, IMMUNOGENICITY, AND ANTITUMOR ACTIVITY OF MEDI3726 IN SUBJECTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE RECEIVED PRIOR TREATMENT WITH ABIRATERONE OR ENZALUTAMIDE

**Cancer types:** Prostate

**Lines of therapy:** 3rd Line+ Metastatic

**HEMREF 50 DDU - 1101-HEM-101**

A PHASE 1 DOSE ESCALATION, MULTICENTER, OPEN LABEL, SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF FT-1101 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

**Cancer types:** Lymphoma/Leukemia, MDS, AML

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 406 DDU - D5660C00004**

A PHASE 1B/2, OPEN-LABEL, MULTICENTER STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOUR ACTIVITY OF MEDI4736 IN COMBINATION WITH AZD9150 OR AZD5069 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES AND SUBSEQUENTLY COMPARING AZD9150 AND AZD5069 BOTH ALONE AND IN COMBINATION WITH MEDI4736 AS SECOND-LINE TREATMENT IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

**Cancer types:** Head & Neck

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 473 DDU - 1381.1**

AN OPEN-LABEL, PHASE I TRIAL TO DETERMINE THE MAXIMUM TOLERATED DOSE AND INVESTIGATE SAFETY, PHARMACOKINETICS AND EFFICACY OF BI 754091 IN PATIENTS WITH ADVANCED SOLID TUMORS.

**Cancer types:** squamous cell skin, Anal, Cervical, tmb >10, Vulvar

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**BRE 283 - 15-102-14**

A PHASE 3 OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY OF NKTR-102 VERSUS TREATMENT OF PHYSICIANS CHOICE (TPC) IN PATIENTS WITH METASTATIC BREAST CANCER WHO HAVE STABLE BRAIN METASTASES AND HAVE BEEN PREVIOUSLY TREATED WITH AN ANTHRACYCLINE, A TAXANE, AND CAPECITABINE

**Cancer types:** Breast ER+, Breast HER2+, Breast Triple Negative

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**LYM 122 - ACE-LY-308**

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF BR ALONE VERSUS IN COMBINATION WITH ACALABRUTINIB (ACP-196) IN SUBJECTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA.

**Cancer types:** Lymphoma/Leukemia

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**MPN 09 - PAC203**

AN OPEN-LABEL, RANDOMIZED, PHASE 2 DOSE-FINDING STUDY OF PACRITINIB IN PATIENTS WITH PRIMARY MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB

**Cancer types:** Myelofibrosis

**Lines of therapy:** 2nd Line Metastatic

**REFMAL 495 DDU - D6520C00001**

A PHASE I, MULTICENTER DOSE-ESCALATION STUDY TO ASSESS THE TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOR ACTIVITY OF AZD5153 IN PATIENTS WITH RELAPSED/REFRACTORY MALIGNANT SOLID TUMORS, INCLUDING LYMPHOMAS

**Cancer types:** Bladder, Breast ER+, Breast Triple Negative, Colorectal, GYN, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Prostate, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 485 DDU - 1381.2**

AN OPEN LABEL, PHASE I DOSE-FINDING STUDY OF BI 754111 AS MONOTHERAPY AND IN COMBINATION WITH BI 754091 IN PATIENTS WITH ADVANCED CANCER FOLLOWED BY EXPANSION COHORTS AT THE RPIID OF THE COMBINATION IN PATIENTS WITH NSCLC AND OTHER TUMOUR TYPES

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous, MSI High, tmb >10

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**CLL 41 - TGR-1202-201**

EVALUATE THE EFFICACY AND SAFETY OF TGR-1202 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WHO ARE INTOLERANT TO PRIOR THERAPY

**Cancer types:** Lymphoma/Leukemia

**Lines of therapy:** 2nd Line Metastatic

**GU 147 - WO39210**

A STUDY OF ATEZOLIZUMAB AS ADJUVANT THERAPY IN PARTICIPANTS WITH RENAL CELL CARCINOMA (RCC) AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY (IMMOTION010)

**Cancer types:** Renal Cell

**Lines of therapy:** Adjuvant

**REFMAL 520 DDU - CP-MGD013-01**

A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION STUDY OF MGD013, A DUAL-AFFINITY RE-TARGETING (DART®) PROTEIN BINDING PD-1 AND LAG-3 IN PATIENTS WITH UNRESECTABLE OR METASTATIC NEOPLASMS

**Cancer types:** Bladder, Breast Triple Negative, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell, MSI High

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 506 DDU - mRNA-4157-P101**

A PHASE 1, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MRNA-4157 ALONE IN SUBJECTS WITH RESECTED SOLID TUMORS AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH UNRESECTABLE SOLID TUMORS

**Cancer types:** Bladder, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, MSI High, tmb >10

**Lines of therapy:** Adjuvant

**LUN 350 - B7461006**

A STUDY OF LORLATINIB VERSUS CRIZOTINIB IN FIRST LINE TREATMENT OF PATIENTS WITH ALK-POSITIVE NSCLC

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GU 142 - CO-338-052**

A STUDY OF RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HOMOLOGOUS RECOMBINATION GENE DEFICIENCY

**Cancer types:** Prostate

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**LUN 358 - D419MC00004**

THIS IS A PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, COMPARATIVE GLOBAL PHASE 3 STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF DURVALUMAB OR DURVALUMAB + TREMELIMUMAB IN COMBINATION THERAPY WITH PLATINUM BASED CHEMOTHERAPY FOR THE FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC).

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GYN 63 - PRO-105**

A PHASE II OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF ACELARIN® (NUC-1031) GIVEN ON DAYS 1, 8 AND 15 OF A 28-DAY SCHEDULE IN PATIENTS WITH RECURRENT PLATINUM-RESISTANT OVARIAN CANCER

**Cancer types:** GYN

**Lines of therapy:** Other

**LYM 132 - INCB 50465-203**

AN OPEN-LABEL, RANDOMIZED STUDY COMPARING INCB050465 TO IDELALISIB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

**Cancer types:** Lymphoma/Leukemia

**Lines of therapy:** 3rd Line+ Metastatic

**BRE 296 - I3Y-MC-JPCF**

A STUDY TO COMPARE TREATMENT AFTER SURGERY OF ABEMACICLIB (LY2835219) COMBINED WITH STANDARD ENDOCRINE THERAPY VERSUS ENDOCRINE THERAPY ALONE IN PARTICIPANTS WITH BREAST CANCER

**Cancer types:** Breast ER+

**Lines of therapy:** Adjuvant

**BRE 287 DDU - H3B-6545-A001-101**

A PHASE I-II MULTICENTER, OPEN LABEL TRIAL OF H3B-6545, A COVALENT ANTAGONIST OF ESTROGEN RECEPTOR ALPHA, IN WOMEN WITH LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR-POSITIVE, HER2 NEGATIVE BREAST CANCER

**Cancer types:** Breast ER+

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 428 DDU - MV-0715-CP-001.01**

PHASE 1 SAFETY AND TOLERABILITY STUDY OF HUMAN MONOCLONAL ANTIBODY MVT-5873 AS MONOTHERAPY AND WITH CHEMOTHERAPY IN SUBJECTS WITH PANCREATIC CANCER OR OTHER CA19-9 POSITIVE MALIGNANCIES

**Cancer types:** Pancreas/Biliary

**Lines of therapy:** 2nd Line Metastatic

**REFMAL 496 DDU - C-700-01**

A PHASE 1 / 2, OPEN-LABEL, MULTIPLE ASCENDING DOSE TRIAL TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, BIOLOGICAL, AND CLINICAL ACTIVITY OF AGEN2034 IN SUBJECTS WITH METASTATIC OR LOCALLY ADVANCED SOLID TUMORS, WITH EXPANSION TO SECOND-LINE CERVICAL CANCER

**Cancer types:** Cervical

**Lines of therapy:** 2nd Line Metastatic

**REFMAL 505 DDU - 1379-0001**

AN OPEN-LABEL PHASE I DOSE FINDING TRIAL WITH BI 891065 IN COMBINATION WITH BI 754091 TO CHARACTERISE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY IN PATIENTS WITH ADVANCED AND/OR METASTATIC MALIGNANCIES

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Neuroendocrine, Prostate, Renal Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 514 DDU - SHRUS 1001**

A TWO-PART PHASE I, OPEN LABEL, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PYROTINIB IN PATIENTS WITH HER2- POSITIVE SOLID TUMORS WHOSE DISEASE PROGRESSED ON PRIOR HER2 TARGETED THERAPY

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Solid Tumor, Her 2 neu mutation

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**GU 150 - CX-839-005**

CB-839 WITH EVEROLIMUS VS. PLACEBO WITH EVEROLIMUS IN PATIENTS WITH RCC

**Cancer types:** Renal Cell

**Lines of therapy:** 3rd Line+ Metastatic

**BRE 297 - MO39196**

A STUDY OF ATEZOLIZUMAB AND PACLITAXEL VERSUS PLACEBO AND PACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER

**Cancer types:** Breast Triple Negative

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**BRE 298 - IMMU-132-05**

AN INTERNATIONAL, MULTI-CENTER, OPEN-LABEL, RANDOMIZED, PHASE III TRIAL OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN CHOICE IN PATIENTS WITH METASTATIC (STAGE IV) TRIPLE-NEGATIVE BREAST CANCER WHO RECEIVED AT LEAST TWO PRIOR TREATMENTS

**Cancer types:** Breast Triple Negative

**Lines of therapy:** 3rd Line+ Metastatic

**MEL 55 - CO39722**

A PHASE III, OPEN-LABEL, MULTICENTER, TWO-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAF WILD-TYPE MELANOMA

**Cancer types:** Melanoma

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GU 137 - E7080-G000-307**

LENVATINIB/EVEROLIMUS OR LENVATINIB/PEMBROLIZUMAB VERSUS SUNITINIB ALONE AS TREATMENT OF ADVANCED RENAL CELL CARCINOMA

**Cancer types:** Renal Cell

**Lines of therapy:** 1st Line Metastatic - Locally Advanced



**LUN 362 - BO29554**

A STUDY TO EVALUATE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PARTICIPANTS WITH NON-SMALL CELL LUNG CANCER

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**BRE 304 - MO39193**

A STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT TRIPLE-NEGATIVE BREAST CANCER

**Cancer types:** Breast Triple Negative

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**REFMAL 545 DDU - CPX-POM-001**

A PHASE 1, FIRST-IN-HUMAN, SAFETY, DOSE TOLERANCE, PHARMACOKINETICS, AND PHARMACODYNAMICS STUDY OF CPX-POM IN PATIENTS WITH ADVANCED SOLID TUMORS

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Neuroendocrine, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 549 DDU - 001-00**

A PHASE 1 STUDY OF MK-5890 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Other

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**GI 256 DDU - TAK-931-2001**

AN OPEN-LABEL, PHASE 2, PARALLEL ARM STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND ACTIVITY OF TAK-931 SINGLE AGENT IN PATIENTS WITH METASTATIC PANCREATIC CANCER OR METASTATIC COLORECTAL CANCER

**Cancer types:** Esophageal, Lung NCSLC Squamous

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**GU 151 DDU - TO-TAS3681-101**

A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, SAFETY, TOLERABILITY, AND PHARMACOKINETIC STUDY OF TAS3681 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER

**Cancer types:** Prostate

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**HEMREF 41 DDU - D6130C00003**

A PHASE I/II, OPEN-LABEL, MULTICENTRE 2-PART STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF AZD2811 NANOPARTICLE IN PATIENTS WITH RELAPSED ACUTE MYELOID LEUKAEMIA/HIGH-RISK MYELODYSPLASTIC SYNDROME OR TREATMENT-NAÏVE PATIENTS NOT ELIGIBLE FOR INTENSIVE INDUCTION THERAPY

**Cancer types:** Lymphoma/Leukemia, Myelofibrosis

**Lines of therapy:** 2nd Line Metastatic

**BRE 303 - ODO-TE-B301**

TESETAXEL PLUS REDUCED DOSE OF CAPECITABINE VS. CAPECITABINE IN HER2 NEGATIVE, HR POSITIVE, MBC

**Cancer types:** Breast ER+

**Lines of therapy:** 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

**LUN 371 - MK-3475-654**

PEMBROLIZUMAB PLUS EPACADOSTAT VS PEMBROLIZUMAB PLUS PLACEBO IN METASTATIC NON-SMALL CELL LUNG CANCER

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**LYM 135 - GO39942**

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH R-CHP VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

**Cancer types:** Lymphoma/Leukemia

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**HEMREF44 DDU - INCB 53914-101**

A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF INCB053914 IN SUBJECTS WITH ADVANCED MALIGNANCIES

**Cancer types:** Myelofibrosis, DLBCL

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**Hemref 55 DDU - 2102-HEM-101**

A PHASE 1/1B, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF FT-2102 AS A SINGLE AGENT AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME WITH AN IDH1 MUTATION

**Cancer types:** MDS, AML, IDH1 mutated

**Lines of therapy:** 2nd Line Metastatic

**REFMAL 529 DDU - 3000-01-002**

PHASE 1B DOSE-FINDING STUDY OF NIRAPARIB OR CARBOPLATIN-PACLITAXEL IN COMBINATION WITH TSR-042 IN PATIENTS WITH ADVANCED OR METASTATIC CANCER

**Cancer types:** Breast ER+, Breast Triple Negative, Colorectal, Gastric, GYN, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Renal Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**LUN 372 - MK-3475-715**

PEMBROLIZUMAB PLUS EPACADOSTAT ALONE OR WITH PLATINUM-BASED CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS PLATINUM-BASED CHEMOTHERAPY PLUS PLACEBO IN METASTATIC NON-SMALL CELL LUNG CANCER

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GYN 78 - 3000-02-004**

PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY

**Cancer types:** GYN

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GI 258 - D419CC00002**

STUDY OF DURVALUMAB AND TREMELIMUMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA

**Cancer types:** Hepatocellular

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GYN 80 - DEK-DKK1-P204**

A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF DKN-01 (HUMANIZED MONOCLONAL ANTIBODY TO DKK1 ) AS A MONOTHERAPY OR IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH RELAPSED/ REFRACTORY ENDOMETRIOID ENDOMETRIAL OR ENDOMETRIOID OVARIAN CANCER

**Cancer types:** GYN

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**GU 118 - D2615C00001**

OPEN-LABEL, RANDOMISED, MULTI-DRUG, BIOMARKER-DIRECTED, PHASE 1B STUDY IN PTS W/ MUSCLE INVASIVE BLADDER CANCER

**Cancer types:** Bladder

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**GI 266 - BGB-290-303**

A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF BGB-290 ( PARP INHIBITOR ) VERSUS PLACEBO AS MAINTENANCE THERAPY IN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER THAT RESPONDED TO PLATINUM-BASED FIRST-LINE CHEMOTHERAPY

**Cancer types:** Gastric

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**BRE 308 - 3000-01-005**

STUDY EVALUATING THE ANTITUMOR ACTIVITY AND SAFETY OF NIRAPARIB AS NEOADJUVANT TREATMENT

**Cancer types:** Breast ER+, Breast Triple Negative

**Lines of therapy:** Neo-Adjuvant

**MM 99 - C16047**

STUDY OF IXAZOMIB+DARATUMUMAB+DEXAMETHASONE (IDD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

**Cancer types:** Myeloma

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**LUN 385 - AM0010-201**

A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NSCLC WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**MDS 21 - P-3001**

PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PARTICIPANTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML), OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (AML)

**Cancer types:** Hematology/Other, MDS, AML

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**LUN 380 - GO40920**

A STUDY OF MTIG7192A IN COMBINATION WITH ATEZOLIZUMAB IN CHEMOTHERAPY-NAÏVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**LYM 138 DDU - ACE-LY-111**

PRISM: A PLATFORM PROTOCOL FOR THE TREATMENT OF RELAPSED/REFRACTORY AGGRESSIVE NON-HODGKIN'S LYMPHOMA

**Cancer types:** Lymphoma/Leukemia

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 543 DDU - JAB-3068-01**

A PHASE 1, MULTI-CENTER, DOSE ESCALATION, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF JAB-3068 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 560 DDU - 1403-0001**

A PHASE IA/IB, OPEN LABEL, MULTICENTER, DOSE-ESCALATION STUDY OF BI 907828 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 562 DDU - BDB001-101**

A PHASE 1 OPEN-LABEL DOSE ESCALATION STUDY OF BDB001 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED SOLID TUMORS

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 563 DDU - 034-00**

A PHASE II STUDY OF NAVARIXIN (MK-7123) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PARTICIPANTS WITH SELECTED ADVANCED/METASTATIC SOLID TUMORS

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Prostate

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**LUN 384 - CACZ885T2301**

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF CANAKINUMAB VERSUS PLACEBO AS ADJUVANT THERAPY IN ADULT SUBJECTS WITH STAGES AJCC/UICC V. 8 II-III A AND III B (T>5CM N2) COMPLETELY RESECTED (R0) NON-SMALL CELL LUNG CANCER

**Cancer types:** Lung NCSLC Non-Squamous, Lung NCSLC Squamous

**Lines of therapy:** Adjuvant

**GU 161 - CB-839-008**

CB-839 WITH CABOZANTINIB VS. CABOZANTINIB WITH PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

**Cancer types:** Renal Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**MM 90 - EFC12522**

RANDOMIZED, OPEN LABEL STUDY ASSESSING THE CLINICAL BENEFIT OF SAR650984, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE COMBINATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR TRANSPLANT

**Cancer types:** Myeloma

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GI 261 - CA209-9X8**

AN INVESTIGATIONAL IMMUNOTHERAPY STUDY OF NIVOLUMAB WITH STANDARD OF CARE THERAPY VS STANDARD OF CARE THERAPY FOR FIRST-LINE TREATMENT OF COLORECTAL CANCER THAT HAS SPREAD

**Cancer types:** Colorectal

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**REFMAL 574 DDU - 64619178ED11001**

A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL STUDY OF THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF JNJ-64619178, AN INHIBITOR OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) IN SUBJECTS WITH ADVANCED CANCERS

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Lymphoma/Leukemia, Melanoma, Prostate, Renal Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**GI 268 - EF-27**

EFFECT OF TUMOR TREATING FIELDS (TTFIELDS, 150 KHZ) AS FRONT-LINE TREATMENT OF LOCALLY-ADVANCED PANCREATIC ADENOCARCINOMA CONCOMITANT WITH GEMCITABINE AND NAB-PACLITAXEL

**Cancer types:** Pancreas/Biliary

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GU 162 - D933IC00003**

STUDY OF DURVALUMAB ALONE AND DURVALUMAB+OLAPARIB IN ADVANCED, PLATINUM-INELIGIBLE BLADDER CANCER

**Cancer types:** Bladder

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GI 274 - M14-064**

A STUDY OF ABT-165 PLUS FOLFIRI VS BEVACIZUMAB PLUS FOLFIRI IN SUBJECTS WITH METASTATIC COLORECTAL CANCER PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE/ OXALIPLATIN AND BEVACIZUMAB

**Cancer types:** Colorectal

**Lines of therapy:** 2nd Line Metastatic

**REFMAL 507 DDU - TAB001-01**

A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAB001 IN SUBJECTS WITH ADVANCED MALIGNANCIES

**Cancer types:** Esophageal, Gastric, Head & Neck, Hepatocellular, Sarcoma

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 585 DDU - RMC-4630-01**

A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY OF RMC-4630 MONOTHERAPY IN ADULT PARTICIPANTS WITH RELAPSED/REFRACTORY SOLID TUMORS

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Melanoma, Prostate, Renal Cell, MSI High, tmb >10

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 578 DDU - KL166-I-01**

A PHASE I-II, FIRST-IN-HUMAN STUDY OF A166 IN PATIENTS WITH LOCALLY ADVANCED/METASTATIC SOLID TUMORS WHICH ARE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE WHO DID NOT RESPOND OR STOPPED RESPONDING TO APPROVED THERAPIES AND PATIENTS WITH HER2 POSITIVE (BY ISH OR NGS) OR LOW EXPRESSING (BY IHC) SOLID TUMORS WHO DID NOT RESPOND OR STOPPED RESPONDING TO APPROVED THERAPIES

**Cancer types:** Solid Tumor, Her 2 neu mutation

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**GI 279 - MK7690-046**

A PHASE 2 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF VICRIVIROC (MK-7690) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PARTICIPANTS WITH ADVANCED/METASTATIC MICROSATELLITE STABLE (MSS) COLORECTAL CANCER (CRC)

**Cancer types:** Colorectal

**Lines of therapy:** 3rd Line+ Metastatic

**LYM 145 - RP6530-1802**

AN OPEN LABEL, PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TENALISIB (RP6530), A NOVEL PI3K  $\alpha/\beta$  DUAL INHIBITOR IN ADULT PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA (INHL)

**Cancer types:** Lymphoma/Leukemia

**Lines of therapy:** 3rd Line+ Metastatic

**GU 164 - 516-003**

PHASE 2 STUDY OF SITRAVATINIB AND NIVOLUMAB IN ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

**Cancer types:** Bladder

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 446 DDU - 204691**

A PHASE I OPEN LABEL STUDY OF GSK3359609 ADMINISTERED ALONE AND IN COMBINATION WITH ANTICANCER AGENTS IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMORS

**Cancer types:** Bladder, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Melanoma, MSI High

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 595 DDU - mRNA-2752-P101**

A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF MRNA-2752, A LIPID NANOPARTICLE ENCAPSULATING MRNAS ENCODING HUMAN OX40L, IL-23, AND IL-36?, FOR INTRATUMORAL INJECTION ALONE AND IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE

**Cancer types:** Breast HER2+, Breast Triple Negative, Head & Neck, Melanoma

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

